Long-term follow-up care needed for children surviving cancer: still a long way to go
Menée aux Etats-Unis à partir de données portant sur 23 601 patients ayant survécu à un cancer pédiatrique diagnostiqué avant l'âge de 20 ans, cette étude de cohorte rétrospective analyse l'évolution, sur la période 1970-1999, du risque de maladies chroniques et de survenue d'événements indésirables (durée médiane de suivi : 21 ans)
In 1975, Giulio D'Angio expressed his concerns about the late effects in cancer survivors and encouraged researchers and clinicians to set up studies to characterise these emerging late effects stating, “It is clear that the child cured of cancer must be followed for life, not so much because late recurrence of disease is feared as to permit detection of the delayed consequences of radio- and chemotherapy. Careful studies of these late effects must be conducted.”
The Lancet Oncology , commentaire, 2017